Test blood-based laser scan to guide first-line breast cancer treatment
Part of Cancer clinical trials.
This Phase 2 study uses a specialized laser test on a blood sample to predict how well palbociclib plus letrozole or anastrozole will work. It’s for certain postmenopausal women with HER2-negative, hormone-receptor positive, advanced (stage IIIb/IV) breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who is postmenopausal, or you are pre/peri-menopausal but your ovaries have been removed (preferred) or you’re using an ovarian-suppression medicine
- Your breast cancer is ER-positive (estrogen receptor positive) and HER2-negative
- Your cancer is stage IIIb or stage IV, and you have at least one measurable/evaluable spot the doctors can track
- You have not had other drug treatment for advanced disease (or your prior hormone therapy timing fits the study’s pattern)
- Your blood counts and liver/kidney tests are within required limits
- You can’t be pregnant or breastfeeding, and you must use reliable non-hormonal birth control during treatment and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well a treatment plan using palbociclib followed by talazoparib (and possibly atezolizumab) works in certain people with advanced ER-positive breast cancer. It may help by targeting cancer biology linked to BRCA/HRD changes and by strengthening how the cancer is controlled.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This study checks for early signs that ER-positive, HER2-negative breast cancer may be coming back by testing your blood for cancer DNA. If signs are found, it tests whether adding palbociclib plus fulvestrant works better than standard hormone therapy alone to prevent recurrence.
This trial tests if a higher dose of palbociclib together with hydroxychloroquine and hormone therapy works better than the standard dose of palbociclib with hormone therapy. It is for people with hormone receptor-positive, HER2-negative breast cancer that has spread and has not been treated yet.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Hear when a new Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.